Key Opinion Leaders are members of a community whose advice is respected by peers and others in their respective fields. Generally, KOLs are physicians and academicians.
Thelansis offers KOL engagement, KOL opinion, KOL insights, clinical trial analytics, rare disease research, rare disease knowledge and clinical trial landscape services for the global pharma and healthcare industry.
With effective KOL engagement, we ensure a sustainable relationship with KOLs.
Roots Analysis has done a detailed study on Targeted Protein Degradation Market: Focus on Therapeutics and Technology Platforms (based on Degronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic Tags, IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs, Protein Homeostatic Modulators, SARDs, SERDs, SNIPERs, and Specific BET and DUB Inhibitors), 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
To order this 330+ page report, which features 130+ figures and 145+ tables, please visit this link Key Market InsightsMore than 85 small molecule protein degraders are currently being evaluated for the treatment of various disease indications; in addition, there are 25+ technology platforms available for use in therapy development effortsThe pipeline features a variety of candidate drugs that target a wide range of disease-causing / associated proteins; majority of the existing drug candidates are designed for administration via non-invasive routesAlthough start-ups and mid-sized firms are spearheading the innovation, several big pharmaceutical companies are also engaged in this domainClose to 5,500 patients were estimated to have been enrolled in clinical trials worldwide, evaluating a number of relevant pre-marketing end points across various phases of developmentA number of prominent scientists from renowned universities have emerged as key opinion leaders, owing to their active involvement in clinical development effortsPublished scientific literature indicates that both industry and academic players have made equal contributions to the innovation in this field; the major focus of such studies is presently on PROTACsForeseeing a lucrative future, several private and public investors have invested over USD 3.5 billion across close to 100 instances of funding since 2014The increasing interest in this field is also reflected in recent partnership activity; most of these deals are focused on novel technology platforms, involving the active participation of both international and indigenous companiesShort term opportunity in this market is likely to be driven by licensing activity, depending on the capability of novel technologies to meet protein degrader design and development needsAs multiple mid-late stage drug candidates are approved for marketing, the long term opportunity is likely to be distributed across different types of protein degraders, target therapeutic areas and various global regions For more information please visit:https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html Table of Contents PREFACE1.1.
Selective Hormone Receptor Degraders (SHRDs)3.8.2.
Targeted Protein Degradation-based Therapeutics and Technologies: Development Pipeline4.2.1.
KOL Profile (Edward O’Mara) PUBLICATION ANALYSIS8.1.
Targeted Protein Degradation-based Therapeutics and Technologies Market for Neurodegenerative Disorders, 2020-203011.3.4.2.
Additionally, Professional Business Logo Design is an uphill task that consists of various insights that every Professional logo designer ought to know. Noteworthy Insights of The Best Professional Logo Design
